Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on February 26, 2024, reporting events occurring on February 24, 2024. The filing addresses a significant executive transition within the company's financial leadership.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: David Arkowitz is retiring as Executive Vice President and Chief Financial Officer, effective March 15, 2024.
- Appointment of New CFO: Marella Thorell has been appointed to succeed Mr. Arkowitz as Executive Vice President and Chief Financial Officer, effective March 25, 2024.
- Interim Leadership: Eric Shaff, President and CEO, will serve as interim principal financial officer and principal accounting officer between March 15 and March 25, 2024, without additional compensation.
Compensation, Outlook, and Risks
New CFO Compensation (Marella Thorell):
- Annual base salary: $480,000.
- One-time cash sign-on bonus: $80,000.
- Annual discretionary bonus: Up to 40% of base salary.
- Equity: Option to purchase 700,000 shares of common stock, vesting 25% on the first anniversary and 6.25% quarterly thereafter.
- Severance: 12 months of base salary and COBRA coverage upon termination without cause or for good reason; additional lump sum equal to 1.0x target bonus if termination occurs near a change in control.
Retiring CFO Arrangements (David Arkowitz):
- Separation Agreement: 12 months of continued base salary and COBRA coverage.
- Advisory Agreement: Six-month consulting role at $500/hour, expected up to 10 hours per month. This service counts toward equity vesting.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the executive transition. Actual results may differ due to risks outlined in the company's Form 10-Q filed on November 2, 2023.
Investor Verification Checklist
- Verify the exact effective dates for the CFO transition (March 15 and March 25, 2024).
- Review the full text of the Employment Agreement and Separation Agreement for specific definitions of "cause" and "good reason."
- Confirm the impact of the interim CFO period on the company's financial reporting timeline.
- Check the company's most recent Form 10-Q for current liquidity and cash runway, as this 8-K does not provide updated financial figures.